Non-Alcoholic Steatohepatitis (NASH) H1, 2020: Pipeline Landscape; Therapeutics Development & Assessment, Drug Profiles, Dormant Projects, Discontinued Products
DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The "Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This report provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.
The Pharmaceutical and Healthcare pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 53, 49, 1, 7, 164, 66 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.
Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Report Scope
-- The pipeline guide provides a snapshot of the global therapeutic
landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
-- The pipeline guide reviews pipeline therapeutics for Non-Alcoholic
Steatohepatitis (NASH) (Gastrointestinal) by companies and
universities/research institutes based on information derived from
company and industry-specific sources.
-- The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and undisclosed
stages.
-- The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing and
collaboration details, R&D brief, MoA & other developmental activities.
-- The pipeline guide reviews key companies involved in Non-Alcoholic
Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all
their major and minor projects.
-- The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH)
(Gastrointestinal) therapeutics based on mechanism of action (MoA), drug
target, route of administration (RoA) and molecule type.
-- The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-- The pipeline guide reviews latest news related to pipeline therapeutics
for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
Reasons to Buy
-- Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-- Recognize emerging players with potentially strong product portfolio and
create effective counter-strategies to gain competitive advantage.
-- Find and recognize significant and varied types of therapeutics under
development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
-- Classify potential new clients or partners in the target demographic.
-- Develop tactical initiatives by understanding the focus areas of leading
companies.
-- Plan mergers and acquisitions meritoriously by identifying key players
and it's most promising pipeline therapeutics.
-- Formulate corrective measures for pipeline projects by understanding
Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth
and focus of Indication therapeutics.
-- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-- Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Key Topics Covered
1. Introduction
2. Non-Alcoholic Steatohepatitis (NASH) - Overview
3. Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Development
4. Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Assessment
5. Non-Alcoholic Steatohepatitis (NASH) - Companies Involved in Therapeutics
Development
6. Non-Alcoholic Steatohepatitis (NASH) - Drug Profiles
7. Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects
8. Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products
9. Non-Alcoholic Steatohepatitis (NASH) - Product Development Milestones
10. Appendix
Companies Mentioned
-- 89bio Ltd
-- ABIONYX Pharma SA
-- Abivax SA
-- Acquist Therapeutics
-- AdAlta Ltd
-- Affinicon ApS
-- Afimmune Biopharma Ltd
-- Akero Therapeutics Inc
-- Albireo Pharma Inc
-- Aldeyra Therapeutics Inc
-- Algernon Pharmaceuticals Inc
-- Aligos Therapeutics Inc
-- Allergan Plc
-- Allysta Pharmaceuticals Inc
-- Alnylam Pharmaceuticals Inc
-- Altavant Sciences Inc
-- Alteogen Inc
-- Altimmune Inc
-- Amgen Inc
-- Angion Biomedica Corp
-- AptaBio Therapeutics Inc
-- Aptamer Sciences Inc
-- AptamiR Therapeutics Inc
-- Araim Pharmaceuticals Inc
-- Arcturus Therapeutics Ltd
-- Arkay Therapeutics LLC
-- Arrowhead Pharmaceuticals Inc
-- ARTham Therapeutics Inc
-- Ascletis Inc
-- Asdera
-- Assembly Biosciences Inc
-- AstraZeneca Plc
-- Auransa Inc
-- Avaliv Therapeutics Inc
-- Axcella Health Inc
-- BBN Cardio Therapeutics
-- BerGenBio ASA
-- Betagenon AB
-- Bioio LLC
-- Bird Rock Bio Inc
-- Blade Therapeutics Inc
-- BLR Bio LLC
-- Boehringer Ingelheim International GmbH
-- Bristol-Myers Squibb Co
-- Buto Biopharma Inc
-- Cadila Healthcare Ltd
-- Califia Bio Inc
-- Can-Fite BioPharma Ltd
-- Carmot Therapeutics Inc
-- CellCure
-- Centaurus Therapeutics Inc
-- ChemoCentryx Inc
-- ChemomAb Ltd
-- Chia Tai Tianqing Pharmaceutical Group Co Ltd.
-- China NT Pharma Group Co Ltd
-- Cirius Therapeutics Inc
-- CohBar Inc
-- Coherus BioSciences Inc
-- ConSynance Therapeutics Inc
-- Continuum Biosciences Inc
-- Corbus Pharmaceuticals Inc
-- Corcept Therapeutics Inc
-- Curadim Pharma Co Ltd
-- Cyclerion Therapeutics Inc
-- Cytodyn Inc
-- D&D Pharmatech Co Ltd
-- Daiichi Sankyo Co Ltd
-- Dicerna Pharmaceuticals Inc
-- Dr. Falk Pharma GmbH
-- DURECT Corp
-- Eli Lilly and Co
-- Enanta Pharmaceuticals Inc
-- EncuraGen Inc
-- Engitix Ltd
-- Enleofen Bio Pte Ltd
-- Enyo Pharma SA
-- Enzychem Lifesciences Corp
-- Epitracker Inc
-- Esperion Therapeutics Inc
-- Exicure Inc
-- F. Hoffmann-La Roche Ltd
-- Fochon Pharmaceutical Ltd
-- Forma Therapeutics Inc
-- Future Medicine Co Ltd
-- Galectin Therapeutics Inc
-- Galecto Biotech AB
-- Galmed Pharmaceuticals Ltd
-- Gemphire Therapeutics Inc
-- Gencia LLC
-- General Regeneratives Shanghai Ltd
-- Genfit SA
-- GenKyoTex SA
-- GI Innovation Co Ltd
-- Gilead Sciences Inc
-- Gmax Biopharm Ltd
-- Guangdong East Sunshine Pharmaceutical Co Ltd
-- Guangdong Zhongsheng Pharmaceutical Co Ltd
-- H. Lundbeck AS
-- Hana Pharm Co Ltd
-- Hanmi Pharmaceuticals Co Ltd
-- HemoShear Therapeutics LLC
-- Hepagene Therapeutics Shanghai Inc
-- Hepion Pharmaceuticals
-- Heprotech Inc
-- Hinova Pharmaceuticals Inc
-- HotSpot Therapeutics Inc
-- Imago Pharmaceuticals Inc
-- Immupharma Plc
-- Immuron Ltd
-- Indalo Therapeutics Inc
-- Inmune Bio Inc
-- Innovate Biopharmacueticals Inc
-- Innovimmune Biotherapeutics Inc
-- Inorbit Therapeutics AB
-- Integral Molecular Inc
-- Intercept Pharmaceuticals Inc
-- INVENT Pharmaceuticals Inc
-- InventisBio Inc
-- Inventiva
-- Ionis Pharmaceuticals Inc
-- J2H Biotech
-- Jecure Therapeutics Inc
-- Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
-- Joyce Biotech Corp
-- KinDex Pharmaceuticals Inc
-- Kinomedica Pty Ltd
-- Kirrhos Pharmaceuticals LLC
-- KoBioLabs Inc
-- Korea United Pharm Inc
-- Kowa Co Ltd
-- Krisani Bio Sciences Pvt Ltd
-- Kyorin Pharmaceutical Co Ltd
-- Laekna Therapeutics Shanghai Co Ltd
-- LG Chem Ltd
-- LifeMax Laboratories Inc
-- Liminal BioSciences Inc
-- Lin Bioscience Inc
-- Lipidio Pharmaceuticals Inc
-- Lipocine Inc
-- LISCure Biosciences Co Ltd
-- Lynkogen Inc
-- Macrophage Therapeutics Inc
-- Madrigal Pharmaceuticals Inc
-- Mallinckrodt Plc
-- Max Biopharma Inc
-- Melior Pharmaceuticals I Inc
-- Merck & Co Inc
-- Metabolic Solutions Development Company LLC
-- Metabolys SAS
-- Metacrine Inc
-- MetiMedi Pharmaceuticals Co Ltd
-- Micelle BioPharma Inc
-- Mina Therapeutics Ltd
-- Mitotherapeutix LLC
-- Mitsubishi Tanabe Pharma Corp
-- Morphic Holding Inc
-- Mperia Therapeutics Inc
-- MYR GmbH
-- Naia Ltd
-- Nanjing Sanhome Pharmaceutical Co Ltd
-- Nanjing Transthera Biosciences Co Ltd
-- NeuroVive Pharmaceutical AB
-- Nexel Co Ltd
-- NGM Biopharmaceuticals Inc
-- Nippon Chemiphar Co Ltd
-- Nivarta Inc
-- NorthSea Therapeutics BV
-- Novartis AG
-- Novo Nordisk AS
-- NuSirt Biopharma Inc
-- Oasis Pharmaceuticals LLC
-- Oramed Pharmaceuticals Inc
-- Osteoneurogen Inc
-- Palo BioFarma SL
-- Pattern Therapeutics
-- PegBio Co Ltd
-- Pfizer Inc
-- pH Pharma Co Ltd
-- Pharmaxis Ltd
-- Phenex Pharmaceuticals AG
-- Pliant Therapeutics Inc
-- Poxel SA
-- Promethera Biosciences SA
-- Protalix BioTherapeutics Inc
-- Proterris Inc
-- PTC Therapeutics Inc
-- RadBio
-- Redx Pharma Plc
-- Regenasome Pty Ltd
-- Regulus Therapeutics Inc
-- reMYND NV
-- Revive Therapeutics Ltd
-- Rhamnopharma Inc
-- Sagimet Biosciences
-- Saje Pharma LLC
-- Salix Pharmaceuticals Ltd
-- Sanofi
-- ScandiCure AB
-- Sciwind Biosciences Co Ltd
-- Scohia Pharma Inc
-- Seal Rock Therapeutics Inc
-- Seres Therapeutics Inc
-- SFA Therapeutics LLC
-- Shanghai Anruite Biological Medicine Technology Co Ltd
-- Shenzhen HighTide Biopharmaceutical Ltd
-- Shionogi & Co Ltd
-- Sihuan Pharmaceutical Holdings Group Ltd
-- Sinew Pharma Inc
-- Sirnaomics Inc
-- SparkBioPharma Inc
-- SteroTherapeutics LLC
-- Suzhou Zelgen Biopharmaceutical Co Ltd
-- Sveikatal Inc
-- Synlogic Inc
-- T3D Therapeutics Inc
-- TaiwanJ Pharmaceuticals Co Ltd
-- Terns Pharmaceuticals Inc
-- TES Pharma SRL
-- Theratechnologies Inc
-- Thetis Pharmaceuticals LLC
-- Tiziana Life Sciences Plc
-- TRACON Pharmaceuticals Inc
-- TreeFrog Therapeutics SAS
-- Valin Technologies Ltd
-- Vascular Biogenics Ltd
-- Vectus Biosystems Ltd
-- Venenum Biodesign LLC
-- Verlyx Pharma Inc
-- Vidasym Inc
-- Viking Therapeutics Inc
-- Visionary Pharmaceuticals Inc
-- Vivus Inc
-- Wave Life Sciences Ltd
-- Xenexus Pharmaceuticals Pty Ltd
-- XORTX Therapeutics Inc
-- YD Life Science Co
-- Yuhan Corp
-- Zafgen Inc
-- Zebra Discovery Ltd
-- Zhejiang Doer Biologics Corp
-- ZyVersa Therapeutics Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/unx36b
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
